Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025)
Aclaris Therapeutics (ACRS) posted quarterly Change in Receivables of -$56000.0 for Q2 2025, down 16.67% year-over-year from -$67200.0 in Q2 2024, and up 17.65% quarter-over-quarter from -$68000.0 in Q1 2025.
Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025) Analysis & Trends
Aclaris Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at -$56000.0 for Q2 2025.
- In Q2 2025, Change in Receivables fell 16.67% year-over-year to -$56000.0; the TTM figure through Jun 2025 stood at -$131000.0 (down 23.58% YoY), while the FY2024 annual figure was $20000.0, up 110.75% from the prior year.
- Change in Receivables for Q2 2025 stood at -$56000.0, up from -$68000.0 in the prior quarter.
- The five-year high for Change in Receivables was $202000.0 in Q1 2023, with the low at -$255000.0 in Q2 2023.
- The 5-year median for Change in Receivables is -$44000.0 (2022), against an average of -$32111.1.
- Peak annual rise in Change in Receivables reached 1920.0% in 2023, while the deepest fall reached 6475.0% in 2023.
- Aclaris Therapeutics' Change in Receivables stood at -$188000.0 in 2021, then surged by 39.89% to -$113000.0 in 2022, then soared by 57.52% to -$48000.0 in 2023, then soared by 47.92% to -$25000.0 in 2024, then sank by 124.0% to -$56000.0 in 2025.
- Business Quant data shows ACRS's Change in Receivables at -$56000.0 in Q2 2025, -$68000.0 in Q1 2025, and -$25000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Aclaris Therapeutics | 808.18 Mn | 716.63 Mn | 1.41 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -56,000.00 |
| Jun 30, 2025 | -56,000.00 |
| Mar 31, 2025 | -68,000.00 |
| Mar 31, 2025 | -68,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Jun 30, 2023 | -255,000.00 |
| Jun 30, 2023 | -255,000.00 |
| Mar 31, 2023 | 202,000.00 |
| Mar 31, 2023 | 202,000.00 |